NCT05740956View on ClinicalTrials.gov

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

June 9, 2023

Primary Completion Date

April 1, 2026

Study Completion Date

October 1, 2026

Conditions
Ovarian CancerBreast CancerPancreatic CancerProstatic CancerColorectal Cancer
Interventions
DRUG

HS-10502

HS-10502 will be administered once per day on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28-day treatment cycle.

Trial Locations (1)

100020

RECRUITING

Cancer Hospital Chinese Acedemy of Medical Sciences, Beijing

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

NCT05740956 - A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter